Remifentanil is commonly used in closely monitored medical environments to provide supportive relief that is generally well-suited for situations requiring short-term, adjustable management of symptoms across several critical acute care domains. It plays a role in managing symptoms that may become intense, which is applicable across conditions characterized by periods of heightened symptoms associated with acute procedures and critical illness.

Analgesia and Supportive Care

The medication is commonly applied to address the need for analgesia during the induction and maintenance of general anesthesia, as well as providing supportive relief into the immediate postoperative period. The medication is relevant for easing acute severe pain and managing the heightened physiological activity triggered by surgery, which may support the maintenance of physiological stability and contribute to the patient's overall comfort during major surgical operations.

In acute clinical settings, Remifentanil is commonly applied to manage acute discomfort and anxiety for critically ill patients in the ICU, particularly those requiring mechanical ventilation. This medication is considered relevant for patients with hepatic or renal impairment, as its breakdown process helps address symptom clusters that otherwise might be associated with prolonged manifestations.

In clinical scenarios where efficient and predictable recovery from anesthesia is appropriate, Remifentanil plays a role in managing unwanted airway reflexes (like coughing or straining) during critical phases, which may assist with maintaining functional stability and support the process of emerging from general anesthesia.

---

Quick Fact: Relief for Acute Severe Pain in highly monitored settings provides support that helps ease the overall symptom burden.

Regulatory References

1. U.S. FDA Drug Label for ULTIVA® (Remifentanil)

Who can and cannot use Remifentanil?

The official eligibility profile for Remifentanil is strictly defined by regulatory documents, outlining populations that are contraindicated, restricted, or approved for use under specific conditions.

---

Contraindications and Absolute Exclusions

• Contraindicated Populations: The medicine is strictly prohibited for patients with a known hypersensitivity to remifentanil or other fentanyl analogs.
• Route Prohibition: It is also contraindicated for epidural or intrathecal administration due to the presence of glycine in the formulation.

---

Age and Conditional Eligibility

Eligibility Status	Population / Age Group	Condition / Context
Approved Use	Adults (18+ years)	General anesthesia, ICU ventilation analgesia.
Approved Use	Children 1–12 years	Maintenance of general anesthesia.
Not Recommended	Under 18 years	Analgesia in mechanically ventilated ICU patients.
Caution Required	Older Adults (65+ years)	May exhibit increased sensitivity to effects.

---

Condition-Specific Restrictions

Eligibility is maintained in patients with severe hepatic or renal impairment, as the pharmacokinetics of the parent drug remain unchanged. However, conditional use requiring close monitoring is necessary for patients with pre-existing conditions such as increased intracranial pressure, head injury, or severe respiratory compromise. The label also indicates that use during pregnancy may cause fetal harm and is associated with the risk of Neonatal Opioid Withdrawal Syndrome.

Interactions with other medicines and products

The official regulatory profile for Remifentanil is defined by critical pharmacodynamic interactions and administration constraints rather than common CYP-mediated pharmacokinetic concerns.

Interaction Scope

Category	Official Regulatory Statement
Interacting Substances	Central Nervous System (CNS) Depressants (including Alcohol); Serotonergic Drugs; Mixed Agonist/Antagonist Opioids; Blood Products.
Mechanistic Basis	Pharmacodynamic Potentiation (additive CNS depression); Functional Inactivation (by non-specific esterases in blood products); Pharmacodynamic Risk (Serotonin Syndrome).
Population Note	Elderly patients (age ge 65 years) exhibit increased pharmacodynamic sensitivity. Clearance is unaffected by hepatic or renal impairment.

---

Interaction Classifications

The most significant warnings concern pharmacodynamic reinforcement:

• CNS Depressants: Co-administration with benzodiazepines, other opioids, or general anesthetics results in synergistic CNS depression, formally associated with the risk of profound sedation, respiratory depression, coma, and death.
• Procedural Constraint: The drug must not be administered into the same intravenous tubing or cannula with blood, plasma, or serum to prevent its functional inactivation by esterases present in these products.
• Other Warnings: Formal regulatory warnings identify the risk of Serotonin Syndrome when Remifentanil is co-administered with serotonergic drugs, and the potential for reduced analgesic effect or precipitated withdrawal when used with mixed agonist/antagonist opioids.

The interaction structure is defined by the high severity of CNS potentiation and mandatory procedural rules related to the drug's rapid, esterase-mediated metabolism.

Remifentanil functions as an agonist with high selectivity for the mu-opioid receptor ( MOR), a G protein-coupled receptor located primarily within the central nervous system (CNS), including the spinal cord and periaqueductal gray area.

Binding of remifentanil to the MOR activates the receptor, inducing a conformational change that promotes the exchange of GTP for GDP on the inhibitory G i/ o protein complex. The activated Galpha i/ o subunit subsequently inhibits adenylate cyclase ( AC), leading to a reduction in intracellular cyclic adenosine monophosphate ( cAMP) levels.

Simultaneously, the dissociated Gbetagamma subunits regulate ion channel activity. They open G protein-coupled inwardly rectifying potassium channels ( GIRK), promoting potassium efflux and subsequent hyperpolarization of the postsynaptic neuron. Furthermore, they inhibit voltage-gated calcium channels ( VGCCs) on the presynaptic terminal, reducing calcium influx.

These combined intracellular events decrease neuronal excitability and inhibit the release of excitatory neurotransmitters (e.g., Substance P, glutamate) from the presynaptic terminals of primary afferent nociceptors. This results in the system-level physiological consequence of modulated central pain transmission, characterized by a dampened afferent sensory signal reaching higher brain centers, and central respiratory drive depression.

Remifentanil is a potent opioid analgesic that is strictly administered by healthcare professionals via intravenous (IV) infusion or IV bolus injection in controlled clinical environments, such as during surgery or in an intensive care setting, due to its rapid and short duration of action.

Administration and Preparation

Remifentanil comes as a sterile, white to off-white lyophilized powder for injection. Before use, the powder must be reconstituted and then further diluted into an intravenous fluid.

• Reconstitution: The powder is typically reconstituted to a concentration of 1 mg/mL.
• Dilution: The reconstituted solution must be diluted further prior to infusion. The recommended final concentration for an adult continuous IV infusion is often 50 mcg/mL, but this can vary based on the patient's specific needs and the infusion device capabilities, ranging from 20 to 250 mcg/mL.

Important Considerations:

1. Strict IV Use Only: Remifentanil must not be administered via epidural or intrathecal injection because the formulation contains glycine.
2. Infusion Device: Continuous IV infusions should be administered only via a calibrated infusion device.
3. Titration: The rate of infusion is continuously adjusted (titrated) by the anesthesia provider to maintain the desired level of pain relief and/or sedation while monitoring for side effects like respiratory depression.
4. Avoid Bolus in Postoperative/Spontaneously Breathing Patients: IV bolus injections are generally not recommended for postoperative pain management or in spontaneously breathing patients due to a higher risk of adverse events like apnea (cessation of breathing) and muscle rigidity.
5. Setting: Remifentanil should only be used in a setting where personnel trained in the use of potent opioids are present, and equipment for respiratory support and monitoring is immediately available.

Research evidence / Overview of Studies for Remifentanil

---

Evidence for Use During General Anesthesia and Immediate Recovery

Research explored the role of Remifentanil in regimens evaluated during general anesthesia, primarily through Randomized Controlled Trials (RCTs) and meta-analyses involving adult surgical patients. Studies monitored physiological parameters like heart rate and blood pressure and examined how Remifentanil use was evaluated against other opioid treatments that accumulate in the body over time.

Research highlights changes in recovery metrics, reporting patterns related to the time to resume spontaneous breathing and time to extubation when compared to opioids with a longer duration of action. Findings also indicate patterns related to a lower observed usage of co-administered hypnotic anesthetic drugs in the studied groups. Research is still exploring the protocols for managing acute pain following the immediate cessation of the infusion, and the evidence provides limited insight into the specific link between high intraoperative doses and the subsequent observation of Opioid-Induced Hyperalgesia (OIH).

---

Evidence for Analgesia and Sedation in Critical Care

The research explored the use of Remifentanil for patients in the Intensive Care Unit (ICU) who require invasive mechanical ventilation. Studies monitored the ability to adjust pain and comfort levels rapidly due to the medication’s short duration of action. Research reports patterns related to the time required to discontinue mechanical ventilation when the medication was stopped. However, findings were mixed and heterogeneous across studies regarding the specific outcomes related to the overall duration of ICU stay.

Long-term effects are not fully established; there is limited information for long-term outcomes following prolonged use.

---

Evidence in Special Populations

Research explored the drug's properties in specific groups, including patients with hepatic or renal impairment and pediatric patients, mainly through Pharmacokinetic (PK) assessments. Data suggest that Remifentanil's clearance appears to be not significantly altered in patients with pre-existing kidney or liver problems. However, data for certain groups, especially large cohorts of pediatric patients, remain insufficient, and the long-term clinical outcomes for these special populations are not fully established through large-scale RCTs.

---

What Research Gaps and Uncertainties Remain

The follow-up durations were limited across many key studies, mainly focusing on acute changes. This means that comparative evidence is lacking regarding the long-term outcomes for patients who receive Remifentanil compared to those who receive other analgesic regimens. Evidence quality varies across studies, particularly in specialized areas like labor analgesia and complex economic analyses of ICU care, where findings were mixed or heterogeneous.

Key Studies & References ULTIVA (Remifentanil) Injection, Lyophilized Powder (U.S. FDA Drug Label / DailyMed)

Common questions about Remifentanil (FAQ)

Q: How quickly does the pain relief start once the Remifentanil infusion begins?

Official regulatory documents indicate that Remifentanil has a rapid onset of action. The maximum pain relief and associated physiological effects are typically observed within three to five minutes after the start of the infusion or a change in the infusion rate. This rapid action is noted as a key characteristic of the drug's profile.

Q: Are there any pre-existing heart conditions that would make a patient ineligible for Remifentanil?

The official product information warns that Remifentanil can cause severe cardiovascular depression. This includes the potential for a decrease in both blood pressure (hypotension) and heart rate (bradycardia). Due to these known effects, official guidance indicates that cardiac function requires close monitoring when the medication is started or adjusted.

Q: What is the research evidence regarding Remifentanil's use in children and adolescents (pediatric patients)?

Official regulatory data confirms that the safety and effectiveness of Remifentanil have been established for use as an analgesic component of general anesthesia in children aged 1 to 12 years. However, its use for sedation in the intensive care unit (ICU) is generally not recommended for patients under 18 years old because adequate studies are currently lacking for that specific context.

Q: Does the body develop tolerance to Remifentanil if it is used for a prolonged period during a long surgery?

Official information states that Remifentanil, like other opioids, can lead to the development of tolerance. Tolerance means that the body requires increasing doses to maintain the same desired effect. Official labeling indicates that this development can occur relatively rapidly during continuous opioid infusion.

Q: What are the main safety concerns that led the FDA to issue a Black Box Warning for Remifentanil?

The FDA has placed a Boxed Warning on the drug to highlight several serious risks. These regulatory warnings emphasize the risks of Addiction, Abuse, and Misuse, as well as the potential for Life-Threatening Respiratory Depression. A key concern is also the increased risk of profound sedation or respiratory compromise when Remifentanil is used at the same time as other central nervous system (CNS) depressants, such as benzodiazepines.

Q: How does Remifentanil compare to Alfentanil in terms of onset and duration of effect?

Clinical studies indicate that Remifentanil is significantly more potent than Alfentanil. The major difference is its pharmacological profile: Remifentanil is broken down by non-specific enzymes in the blood (esterases), resulting in an ultra-short duration of action that is predictable regardless of the length of the infusion.

Q: Does Remifentanil affect a patient's potential for breastfeeding after surgery?

Official regulatory documents recommend that caution should be used when Remifentanil is administered to a breastfeeding mother. Official product information notes that metabolites are excreted into animal milk. Since other similar drugs may be found in human milk, official labeling states that breastfed infants may require monitoring for signs of sedation or respiratory depression.

Q: What is the purpose of using Remifentanil in a Total Intravenous Anesthesia (TIVA) technique?

Remifentanil is utilized as an opioid analgesic component for various general anesthesia techniques, including the induction and maintenance of anesthesia. Its ultra-short and predictable action makes it compatible with the principles of a Total Intravenous Anesthesia (TIVA) approach, which relies exclusively on intravenous medications for control of pain and consciousness.

Q: Is there an increased risk of intraoperative awareness when Remifentanil is used at high doses?

Regulatory guidance states that Remifentanil is not recommended to be used alone as the sole agent for general anesthesia. It is an analgesic (painkiller) only, and its use by itself cannot guarantee that a patient will lose consciousness. Therefore, the drug must always be administered as an adjunct, meaning it is given along with another medication, such as a hypnotic agent, to ensure an adequate anesthetic state.

Q: Can Remifentanil worsen existing conditions like gallbladder problems or pancreatitis?

Official warnings describe that Remifentanil, like all opioid analgesics, has the potential to cause spasms in a duct known as the sphincter of Oddi. This reaction may lead to increases in certain enzymes (serum amylase and lipase). Official information suggests that patients with pre-existing conditions involving the biliary tract, such as acute pancreatitis or gallbladder disease, may require monitoring.

Q: What happens to the remaining drug/metabolites in the body after it has been broken down?

The drug is broken down very quickly in the body into a substance called a carboxylic acid metabolite. This metabolite is considered to be inactive, meaning it does not contribute significantly to the drug's effects. According to official information, this inactive substance is then removed from the body primarily through excretion by the kidneys.

Q: Is it normal to feel disoriented or have unusual dreams when waking up after Remifentanil use?

Official adverse event reports indicate that certain psychiatric effects are possible. Adverse reactions have been reported that include disorientation, confusion, and experiencing nightmares while receiving or recovering from the medication, though the frequency is not always specified.

Q: Can Remifentanil be used in patients with a history of sleep apnea?

Official warnings note that Remifentanil can cause severe respiratory depression (very slow or shallow breathing). Regulatory information states that the risk of breathing problems is greater in patients who have pre-existing chronic pulmonary diseases. Official product information notes that these patients may require particularly close monitoring when the infusion is started and adjusted.

Q: What are the guidelines for adjusting Remifentanil use for patients with low body weight?

Official dosage guidelines emphasize that Remifentanil use must be individualized for each patient. Factors such as the patient’s body weight, their overall physical status, and the type of surgery are all considered when determining the infusion rate. Dosing is often calculated based on the patient's ideal body weight (IBW), rather than their actual weight.

The lyophilized powder form of Remifentanil must be stored in its original container at Controlled Room Temperature (20^circ to 25^circC). The product requires protection from light and excessive moisture, and the powder must not be refrigerated or frozen.

Due to its classification as a potent opioid and controlled substance, Remifentanil must be kept out of the sight and reach of children to prevent accidental ingestion.

After reconstitution and dilution, the prepared solution is typically stable for up to 24 hours at room temperature.

Disposal: The FDA mandates specific procedures for this high-risk medication, recommending the use of a drug take-back program or instructing that unused portions be immediately flushed down a toilet or sink if take-back is not available, to mitigate the serious risk of harm from accidental exposure.